Thank you for sharing that article, P.
Nuvectra was certainly on their way to being a major player, with excellent YOY increases in revenue and implants.
Which makes the Ch 11 all the more strange and unbelievable. Frankly it will absolutely astound me if they are not purchased, and for decent money.
How much would it cost a company to develop a fully functional fda-approved scs system, which is full body mri compliant?
Maybe 150-200 million.
Yet they can probably purchase Algovita outright for $50 million (or less I suppose).
I figure with all debts etc, as long as we get above $30 million common shares should get a nice bump. Legally, the excess has to be paid to unsecured debt, such as stock equity (at least to me it sounds crazy if not).
News 
Market Data 
Discover 
